ACCC Submits Comments to CY2019 Proposed PFS Rule
Three Foundations Commit 30 Million Dollars to Nonprofit Generic Drug Company
CMS Issues Changes to Part D Formulary Options in 2020
FDA Approves Ibrutinib Plus Rituximab for Rare Blood Cancer
FDA Approves Pembrolizumab + Chemotherapy for NSqNSCLC
FDA Updates Prescribing Information for Keytruda and Tecentriq
FDA Approves Nivolumab for Previously Treated SCLC Patients
FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma
HealthWell Foundation Opens Fund for Gastric Cancer Patients
NCCN Publishes Guidelines for Rare Cancers Associated with Pregnancy
FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides, Sézary Syndrome
CMS Gives Medicare Advantage Plans Option to Utilize Step Therapy
FDA Warns Against Long-Term Azithromycin Use for Lung Condition in Cancer Patients
CMS to Hold 8/22 Listening Session on Understanding CY 2019 PFS Proposed Rule
FDA Approves Lusutrombopag for Thromocytopenia
FDA Approves Azedra for Treatment of Rare Adrenal Tumors
CMS Issues CY 2019 Proposed OPPS Rule
GAO Report Compares Characteristics of 340B and non-340B Hospitals
House of Representatives Passes PCHETA, Three Other Workforce Bills
FDA Approves Filgrastim Biosimilar for AML
CMS to Host Webinar Series on 2017 MIPS Feedback; 2018 Performance Categories
FDA Approves Ivosidenib for R/R AML
FDA Approves Ribociclib in Combination for Advanced, Metastatic Breast Cancer
ACCC Submits Comments to Administration's Drug Pricing Blueprint
FDA Approves Enzalutamide for Castration-resistant Prostate Cancer
CMS Issues Proposed CY2019 Physician Fee Schedule & QPP Rule
ACS Launches Series to Outline 21st-Century Blueprint for Cancer Control
NCI, VA Come to Agreement to Improve Veterans' Access to Cancer Clinical Trials
GAO Reports Calls for More Oversight of 340B Contract Pharmacies
CMS Posts MIPS Final Scores, Performance Feedback for Review
